Puma Biotechnology (PBYI) Operating Income (2010 - 2026)

Puma Biotechnology has reported Operating Income for 17 years, with the latest figure at -$3.8 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Income fell 196.08% year-over-year to -$3.8 million; the trailing twelve-month figure through Mar 2026 stood at $29.5 million (down 20.84% YoY), and the FY2025 full-year result was $37.3 million, up 20.45% from the prior year.
• Operating Income for Q1 2026 stood at -$3.8 million, down from $17.1 million in the prior quarter.
• The five-year high for Operating Income was $22.1 million in Q3 2024, with the low at -$3.8 million in Q1 2026.
• Historically, Operating Income has averaged $7.1 million across 5 years, with a median of $6.6 million in 2025.
• Annual changes were most pronounced in 2022 — Operating Income soared 2091.25% — and 2026, when it tumbled 196.08%.
• Puma Biotechnology's Operating Income stood at $10.0 million in 2022, then soared by 47.74% to $14.8 million in 2023, then decreased by 9.68% to $13.4 million in 2024, then climbed by 27.99% to $17.1 million in 2025, then sank by 122.38% to -$3.8 million in 2026.
• The last three Operating Income figures came in at -$3.8 million (Q1 2026), $17.1 million (Q4 2025), and $9.6 million (Q3 2025), per Business Quant data.